JOHNSON & JOHNSON - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
JOHNSON & JOHNSON ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,163,616
-55.5%
3,379,0640.0%2.64%
-47.2%
Q2 2023$16,084,345
-16.5%
3,379,0640.0%4.99%
-20.3%
Q1 2023$19,260,665
+56391.2%
3,379,0640.0%6.26%
-36.8%
Q4 2022$34,095
-100.0%
3,379,0640.0%9.92%
-55.5%
Q3 2022$75,725,000
-9.6%
3,379,0640.0%22.28%
+4.2%
Q2 2022$83,733,000
-36.1%
3,379,0640.0%21.39%
-13.6%
Q1 2022$131,006,000
-33.7%
3,379,0640.0%24.77%
+10.0%
Q4 2021$197,709,000
-1.3%
3,379,0640.0%22.51%
+28.1%
Q3 2021$200,277,0003,379,06417.57%
Other shareholders
FATE THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Polaris Venture Management Co. V, L.L.C. 569,889$46,987,00060.92%
Johnson & Johnson Innovation - JJDC, Inc. 3,379,064$278,604,00036.08%
Darwin Global Management, Ltd. 1,370,133$112,967,00022.12%
Redmile Group, LLC 12,957,222$1,068,323,00015.05%
Copernicus Capital Management, LLC 8,000$660,00010.66%
Casdin Capital, LLC 3,400,000$280,330,0008.35%
Grosvenor Holdings, L.L.C. 1,123,576$92,639,0006.81%
DAFNA Capital Management LLC 314,360$25,919,0006.15%
Ally Bridge Group (NY) LLC 270,000$22,262,0004.27%
Ghost Tree Capital, LLC 185,000$15,253,0003.58%
View complete list of FATE THERAPEUTICS INC shareholders